Aptinyx Inc., of Evanston, Ill., said the FDA granted fast track designation to NYX-2925, its lead compound, to treat neuropathic pain associated with diabetic peripheral neuropathy, or DPN. The company said preclinical data on the drug will be featured in two poster presentations at the 16th World Congress on Pain in Yokohama, Japan, at the end of September. The data show NYX-2925 has potential as an oral therapeutic in DPN without sedative side effects, the company said.